[8] In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns.

[9][10][11] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy.

On March 17, 2021, WuXi Biologics announced an equity agreement with Pfizer China to acquire its newly built $350 million Hangzhou global biotechnology center site and facilities (MFG20).

Along with the controlling stake, WuXi Biologics will also acquire a 7000L bioreactor capacity manufacturing facility (MFG21) in Suzhou and associated liquid and lyophilization (DP21) fill and finish production lines.

The facility performs cell line characterization, viral clearance validation studies, and unprocessed bulk lot release.

[15][19] Currently slated to open in 2022, the Shijiazhuang facility MFG8 will be 884,363 sq ft (82,160.0 m2) and dedicated to development and API manufacturing with an initial bioreactor capacity of 48,000 liters.

[21] On December 21, 2020, WuXi Biologics and Bayer announced a new acquisition agreement for a drug substance (DS) production site for €150 million in Wuppertal, Germany.

When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe.

[27] In June 2020, WuXi Biologics announced that it had signed a ten-year lease for a 66,000 sq ft (6,100 m2) clinical manufacturing facility (MFG18) in Cranbury, NJ.